Results 251 to 260 of about 21,972,715 (300)
Some of the next articles are maybe not open access.
Expression of c-kit in uterine carcinosarcoma
Gynecologic Oncology, 2005The use of tyrosine kinase inhibitors (TKIs) has resulted in successful treatment of KIT-positive neoplasms. Carcinosarcoma is a very aggressive neoplasm. Consequently, c-kit expression may have significant clinical implications for this tumor. The purpose of the present study was to assess c-kit expression in the carcinomatous and sarcomatous element ...
Joseph, Menczer +5 more
openaire +2 more sources
2004
Mast cells (MC) are tissue elements derived from a subset of hematopoietic stem cells expressing CD34, c-kit and CD13 antigens [1] (Fig. 20.1). Immature MC progenitors circulate in the bloodstream then differentiate in tissues under the influence of cytokines, one of utmost importance being stem cell factor (SCF).
Frédéric Féger +3 more
openaire +1 more source
Mast cells (MC) are tissue elements derived from a subset of hematopoietic stem cells expressing CD34, c-kit and CD13 antigens [1] (Fig. 20.1). Immature MC progenitors circulate in the bloodstream then differentiate in tissues under the influence of cytokines, one of utmost importance being stem cell factor (SCF).
Frédéric Féger +3 more
openaire +1 more source
Expression of c-kit in hydatidiform mole
Pathology, 2009Angela T. Byramji and T.
Molga, A., Khong, T.
openaire +3 more sources
C-KIT Signaling in Cancer Treatment
Current Pharmaceutical Design, 2014Tumor progression is strongly associated with the activity of receptor tyrosine kinases (RTKs) and their intracellular signal transduction pathways, which regulate several cell functions including proliferation, apoptosis, motility, adhesion and angiogenesis.
Karmen, Stankov +2 more
openaire +2 more sources
Therapeutic targeting of c-KIT in cancer
Expert Opinion on Investigational Drugs, 2012Mutated forms of the receptor tyrosine kinase c-KIT are "drivers" in several cancers and are attractive targets for therapy. While benefits have been obtained from use of inhibitors of KIT kinase activity such as imatinib, especially in gastrointestinal stromal tumours (GIST), primary resistance occurs with certain oncogenic mutations.
Ashman, Leonie K., Griffith, Renate
openaire +2 more sources
c-kit mutations in gastrointestinal stromal tumours
Pathology, 2002Gastrointestinal stromal tumours (GISTs), once assumed to be of smooth muscle origin, generally express CD117 and CD34, similar to the interstitial cells of Cajal. Assessment of malignant potential in GISTs is problematic, especially on small biopsies.
Morey, Adrienne L. +3 more
openaire +5 more sources
Role of c-kit in Egg Activation
1998In many species a series of Ca2+ oscillations is the first event triggered by egg-sperm fusion (Whitaker and Swann 1993). It is widely accepted that this series of increases in intracellular free Ca2+ is responsible for the following egg activation; however, the molecular mechanisms underlying such Ca2+ mobilization within the egg are not fully ...
ROSSI P. +4 more
openaire +2 more sources
The protooncogene c-kit and c-kit ligand in human disease☆☆☆★
Journal of Allergy and Clinical Immunology, 1997H, Vliagoftis +2 more
openaire +2 more sources
Detection of c-KIT antigen (CD117) and c-kit mRNA in acute leukemia
1996Study population: 29 patients (pts), mean age 50 years (range 18-78), with acute leukemia ( 8 ALL. 21 AML) were studied at diagnosis. Methods:detection of GDI 17 on bone marrow and/or peripheral blood samples was carried out by flow cytometric analysis using a 95C3 monoclonal antibody; positivity was defined as > 20% of stained leukemic cells, c-kit
Cairoli, R +10 more
openaire +1 more source
FOXA2 Drives Lineage Plasticity and KIT Pathway Activation in Neuroendocrine Prostate Cancer
Cancer Cell, 2022Dong Gao, Yiqin Zhu, Pengfei Dai
exaly

